The aim of this study was to determine whether kidney transplantations performed after previous nonrenal solid organ transplants are associated with worse graft survival when there are repeated HLA mismatches (RMM) with the previous donor(s). We performed a retrospective cohort study using data from the Scientific Registry of 
| INTRODUCTION
Chronic kidney disease (CKD) represents a frequent complication after nonrenal solid organ transplantation (SOT), with up to 20% of patients having CKD in the first 5 years after transplantation.
1 Currently, 10%-15% of patients who are waitlisted for a kidney in North America have been exposed to a previous transplantation, renal or nonrenal.
2,3
Kidney transplantations performed after a previous SOT present a higher immunological risk than first transplants, with higher rejection rates 4 and lower graft survival. 4 ,5 Donor-specific anti-HLA antibodies (DSA) develop in approximately 8%-25% of nonrenal SOT. [6] [7] [8] Hence,
a patient who has developed de novo DSA to a first donor may encounter an increased risk of rejection when a kidney transplantation is subsequently performed, if there is DSA to a mismatched HLA antigen shared by the old and the new donor. Although this should be prevented through pretransplant DSA screening, false-negative DSA testing can occur due to low DSA titers, 9 interference by other serum proteins, or assay-dependent technical reasons. 10 Even in the absence of DSA formation, reexposure to a new load of HLA antigens that were present on a previous donor may increase cell-mediated immune response and the risk of rejection through stimulation of memory T cells.
11
Although not all studies have yielded similar results, [12] [13] [14] [15] [16] [17] recent data show that repeated mismatches (RMM) in class 2 are associated with slightly poorer graft survival in kidney transplant patients who had previously received a kidney transplantation and who were sensitized, or had undergone previous graft nephrectomy. 18 To this
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recipients with previous nonrenal SOT. The impact of RMM on graft survival may not be the same in this population when compared to patients with second kidney transplants. Maintenance immunosuppression is not likely to be discontinued in a nonrenal SOT recipient who develops CKD, whereas immunosuppression is often discontinued in renal transplant recipients who fail a first kidney transplant. 19 Lung, heart, pancreas, and intestine transplantations are associated with rates of rejection that are up to twice as high 20-23 when compared to liver or kidney transplants. 24, 25 As rejections may increase the risk of sensitization, 26 the impact of RMM could vary according to the type of organ that was previously transplanted.
Hence, we undertook the present study to determine whether kidney transplantations performed after previous nonrenal SOT are associated with worse graft survival when there are RMM with the previous donor(s). As secondary objectives, we assessed whether this relationship was modified by pretransplant sensitization and the rejection risk of the previous organ transplanted.
| MATERIALS AND METHODS
This retrospective study used data from the Scientific Registry of heart, or combined heart-lung SOT, and "low rejection risk," including recipients of previous liver transplants.
| Statistical analyses
We performed multivariate Cox regressions accounting for withinpatient correlation (ie, a single patient could provide more than 1 index transplantation) to assess the associations between RMM and overall graft loss, death-censored graft loss, and patient death. We examined the impact of 1 or more RMM versus none for all 6 loci, as well as RMM at class 1 and class 2 separately. In addition to the presence of RMM, we included all the factors that were either associated with graft survival based on the results of univariate analyses or on the literature, as well as the factors that were associated with RMM. Given the large number of events that occurred, we made no attempt to simplify the model and did not remove any independent variables. First, we examined the data for the whole cohort. Then, we performed interaction tests and stratified analyses to assess whether the impact of repeated mismatches on overall graft survival were different according to pretransplant sensitization and to the rejection risk of the previous organ transplanted.
| RESULTS
A total of 350 892 kidney transplantations were performed during the study period. After applying the various exclusion criteria, 6624 kidney transplantations performed after previous nonrenal SOT were included in the study ( Figure 1 Including pancreas alone and combined pancreas-kidney (ie, previous organ types include recipients of kidney transplantations performed in combination with nonrenal organs). Some recipients of previous nonrenal organs also had received previous kidney transplantations (n = 1519). 
| Patient characteristics
Selected characteristics of the study population, including the type of the previous SOT, are listed in Table 1 . In kidney transplantations with RMM, recipients and donors were more likely to be older, recipients were more likely to have diabetes or calcineurin-inhibitor toxicity as a cause of CKD, to have had more than 1 previous SOT, to be unsensitized, and to have received previous liver or heart SOT. Living donors and extended-criteria donors were more frequent in kidney Table 3B only), number of previous transplantations, number of HLA mismatches at the index transplantation, previous solid organ type (for Table 3A only), and induction.
transplantations with RMM, and the time elapsed between the index transplantation and the previous one was shorter. As expected, there were more HLA mismatches between the recipient and the donor at the time of the index transplantation in kidney transplantations with RMM. Kidney transplantations with RMM were more likely to have been performed in the most recent era. Use of induction with anti-CD25 was more frequent in kidney transplantations with RMM.
| Association of RMM with outcomes
In kidney transplantations performed in patients who had previously received nonrenal SOT, we found no association between overall graft survival and either class 1 RMM (hazard ratio (Table 3A) or the rejection risk of the previous SOT (Table 3B) 
| DISCUSSION
In patients who previously received a nonrenal SOT, CKD is relatively common, and may lead to the need for kidney transplantation.
However, this patient population is often excluded from large cohort studies because of its heavy and heterogeneous comorbidity burden. 18 In this study, we show for the first time that among patients who previously received a nonrenal SOT, there was no association between RMM and graft survival. Furthermore, we found no effect modification by sensitization, the risk of rejection of the previous SOT, or era of transplantation in the relationship between RMM and graft survival.
Whether RMM are associated with worse graft survival is an important question for transplant physicians, both in terms of deciding on whether to accept an organ for transplantation and of personalizing immunosuppression. Because of the relatively large size of this study, the 95% confidence intervals are narrow, and the upper boundaries suggests that this observation is not related to lack of power but rather to the absence of an association.
Trends in use of maintenance immunosuppressive agents and screening techniques for pretransplant DSA have changed in the last 2 decades. 28, 29 We expected that the relationship between RMM and graft survival would be stronger in the more remote transplant era,
given the lower potency of immunosuppressive agents and lower sensitivity of techniques used for pretransplant DSA screening. However, we found no association between transplant era and the relationship between RMM and graft survival. This may be because of the fact that more than half of graft losses were due to patient death. Hence, the impact of other factors, including function of the nonrenal SOT, is probably more important in predicting graft survival than RMM. The lack of association between RMM and death-censored graft survival also argues for the absence of a strong effect of RMM in predicting graft survival.
It would be of interest to assess the relationship between RMM and rejection rates or rejection-related graft loss. However, rejections are poorly captured into the SRTR, 30 as a recent validation showed a sensitivity for the diagnosis of acute rejection of only 43% when compared to prospective data collection. Data on cause-specific graft loss was missing in 97% of transplantations and could not be assessed. 
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